Show simple item record

dc.contributor.authorMcIlroy, George
dc.contributor.authorTammireddy, Seshu R.
dc.contributor.authorMaskrey, Benjamin H.
dc.contributor.authorGrant, Louise
dc.contributor.authorDoherty, Mary K.
dc.contributor.authorWatson, David G.
dc.contributor.authorDelibegovic, Mirela
dc.contributor.authorWhitfield, Philip D.
dc.contributor.authorMody, Nimesh
dc.date.accessioned2015-12-02T11:27:02Z
dc.date.available2015-12-02T11:27:02Z
dc.date.issued2016-01-15
dc.identifier58987197
dc.identifier7328af86-fd2d-408c-aa83-0dbaa1bfeda1
dc.identifier84963690368
dc.identifier.citationMcIlroy , G , Tammireddy , S R , Maskrey , B H , Grant , L , Doherty , M K , Watson , D G , Delibegovic , M , Whitfield , P D & Mody , N 2016 , ' Fenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissue ' , Biochemical Pharmacology , vol. 100 , pp. 86-97 . https://doi.org/10.1016/j.bcp.2015.11.017en
dc.identifier.issn0006-2952
dc.identifier.otherORCID: /0000-0003-4230-4355/work/102133123
dc.identifier.otherORCID: /0000-0002-2215-7952/work/147568329
dc.identifier.urihttp://hdl.handle.net/2164/5265
dc.descriptionAcknowledgments This work was supported by the British Heart Foundation Intermediate Basic Research Fellowship FS/09/026/27398 to NM., the Biotechnology and Biological Sciences Research Council doctoral training grant awarded to GDM and the Wellcome Trust and the University of Aberdeen ISSF Fund to NM and LG and The Royal Society (of London) to NM. SRT, BHM, MKD and PDW gratefully acknowledge Highlands and Islands Enterprise, Scottish Funding Council and the European Regional Development Fund for financial support. The authors thank Tonya Martin (Johnson & Johnson, New Brunswick, NJ), and Urs Thurneer (Cilag AG, Schaffhausen, Switzerland) for the generous gift of Fenretinide to use completely without restriction or obligation. The authors thank Tonya Martin (Johnson & Johnson, New Brunswick, NJ), and Urs Thurneer (Cilag AG, Schaffhausen, Switzerland) for the generous gift of Fenretinide to use completely without restriction or obligation.en
dc.format.extent12
dc.format.extent3776676
dc.language.isoeng
dc.relation.ispartofBiochemical Pharmacologyen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectfenretinideen
dc.subjectretinoic aciden
dc.subjectadipocytesen
dc.subjectmetabolomicsen
dc.subjectdihydroceramideen
dc.subjectlipidomicsen
dc.subjectRM Therapeutics. Pharmacologyen
dc.subjectBritish Heart Foundationen
dc.subjectFS/09/026/27398en
dc.subjectWellcome Trusten
dc.subjectBiotechnology and Biological Sciences Research Council (BBSRC)en
dc.subjectScottish Funding Councilen
dc.subject.lccRMen
dc.titleFenretinide mediated retinoic acid receptor signalling and inhibition of ceramide biosynthesis regulates adipogenesis, lipid accumulation, mitochondrial function and nutrient stress signalling in adipocytes and adipose tissueen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Rowett Instituteen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Medical Sciences - Cardiovascular Groupen
dc.description.statusPeer revieweden
dc.identifier.doi10.1016/j.bcp.2015.11.017


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record